| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 29.46% | 1.45% | 16.79% | 17.07% | 19.62% | -9.89% | 18.62% | 6.87% | -15.87% | 13.11% | 6.72% | -0.94% |
| EBITDA Margin | 31.28% | 3.55% | 19.03% | 19.07% | 21.55% | -7.94% | 21.15% | 9.79% | -12.47% | 18.40% | 12.67% | 7.16% |
| Net Margin | 25.03% | 0.77% | 16.17% | 10.04% | 31.76% | -11.09% | 20.70% | 5.82% | -20.38% | 9.43% | — | — |
| Current Ratio | 3.32 | 1.97 | 3.75 | 3.54 | 3.65 | 3.74 | 4.83 | 4.31 | 4.01 | 3.64 | 5.01 | 3.16 |
| Quick Ratio | 3.25 | 1.94 | 3.69 | 3.50 | 3.62 | 3.71 | 4.81 | 4.29 | 3.99 | 3.62 | 5.00 | 3.15 |
| Debt / Equity | — | — | — | — | — | — | — | 9.91 | 0.02 | 1.79 | 4.38 | -9.25 |
| ROE | 24.90% | 0.95% | 11.51% | 7.80% | 25.16% | -11.32% | 17.20% | 5.69% | -19.20% | 24.85% | — | — |
| ROA | 18.49% | 0.60% | 8.81% | 5.83% | 19.23% | -8.30% | 13.04% | 4.14% | -13.60% | 6.36% | — | — |
| Asset Turnover | 0.74 | 0.78 | 0.54 | 0.58 | 0.61 | 0.75 | 0.63 | 0.71 | 0.67 | 0.67 | 0.75 | 0.62 |
| Book Value / Share | 25.75 | 16.38 | 22.97 | 19.51 | 16.98 | 11.97 | 11.94 | 8.93 | 7.97 | 2.16 | 0.91 | -0.49 |
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics for serious medical conditions. The company concentrates on hematology and oncology, as well as inflammation, autoimmunity, and dermatology, addressing diseases with significant unmet medical needs. A core part of its business is small-molecule drug development, supported by a broad pipeline of oncology and dermatology programs. Incyte’s portfolio includes Jakafi for certain rare blood cancers and graft-versus-host disease, along with partnered and licensed therapies such as Olumiant for rheumatoid arthritis, Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma. The company also markets Opzelura, a topical treatment for atopic dermatitis and vitiligo in dermatology. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte plays a notable role in the healthcare and biotechnology sectors by providing targeted therapies that are integrated into specialized care across global markets.